

Cardiovascular implants - Endovascular devices - Part 2:
Vascular stents (ISO 25539-2:2020)

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

See Eesti standard EVS-EN ISO 25539-2:2020 sisaldab Euroopa standardi EN ISO 25539-2:2020 ingliskeelset teksti.	This Estonian standard EVS-EN ISO 25539-2:2020 consists of the English text of the European standard EN ISO 25539-2:2020.
Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas	This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation.
Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 30.09.2020.	Date of Availability of the European standard is 30.09.2020.
Standard on kättesaadav Eesti Standardikeskusest.	The standard is available from the Estonian Centre for Standardisation.

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.040.40

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardikeskusele

Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardikeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autorikaitse kohta, võtke palun ühendust Eesti Standardikeskusega:
Koduleht www.evs.ee; telefon 605 5050; e-post info@evs.ee

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation

No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation.

If you have any questions about copyright, please contact Estonian Centre for Standardisation:

Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee

English Version

Cardiovascular implants - Endovascular devices - Part 2:
Vascular stents (ISO 25539-2:2020)

Implants cardiovasculaires - Dispositifs
endovasculaires - Partie 2: Endoprothèses vasculaires
(ISO 25539-2:2020)

Kardiovaskuläre Implantate - Endovaskuläre
Implantate - Teil 2: Gefäßstents (ISO 25539-2:2020)

This European Standard was approved by CEN on 20 August 2020.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 25539-2:2020) has been prepared by Technical Committee ISO/TC 150 "Implants for surgery" in collaboration with Technical Committee CEN/TC 285 "Non-active surgical implants" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by March 2021, and conflicting national standards shall be withdrawn at the latest by March 2021.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 25539-2:2012.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 25539-2:2020 has been approved by CEN as EN ISO 25539-2:2020 without any modification.

Contents

Page

Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 General requirements for stent systems	6
4.1 General	6
4.2 Type of stent	6
4.3 Materials of construction for stent system	6
4.4 Configuration and size designation for stents and stent systems	6
4.5 Intended clinical use designation	7
4.6 Balloon designation	8
5 Intended performance	8
6 Design attributes	8
6.1 General	8
6.2 Stent system	8
6.3 Stent	8
6.4 Stent system and stent	9
6.5 Coating on delivery system or stent	9
6.6 Coating on stent	9
6.7 Absorbable stent or coating	9
6.8 Drug-eluting stent	10
7 Materials	10
8 Design evaluation	10
8.1 General	10
8.2 Sampling	11
8.3 Conditioning of test samples	12
8.4 Reporting	12
8.5 Bench and analytical tests	13
8.5.1 Stent system and delivery system	13
8.5.2 Stent	16
8.5.3 Absorbable stents and stents containing an absorbable coating	22
8.5.4 Coating on a delivery system	22
8.5.5 Coating on a stent	22
8.5.6 Drug-containing stent	22
8.6 Preclinical <i>in vivo</i> evaluation	23
8.6.1 Purpose	23
8.6.2 Specific aims	23
8.6.3 Protocol considerations	24
8.6.4 Data acquisition	24
8.6.5 Test report and additional information	26
8.7 Clinical evaluation	27
8.7.1 Purpose	27
8.7.2 Specific aims	27
8.7.3 Protocol considerations	28
8.7.4 Data acquisition	29
8.7.5 Final report	31
9 Post-market surveillance	32
10 Manufacturing	32
11 Sterilization	32

11.1	Products supplied sterile	32
11.2	Sterilization residuals	33
12	Packaging	33
12.1	General	33
12.1.1	General	33
12.1.2	Unit container	33
12.1.3	Outer container	33
12.1.4	Shipping container	33
12.1.5	Maintenance of sterility in transit	33
12.2	Labelling	33
12.2.1	Container label	33
12.2.2	Stents without delivery systems	33
12.2.3	Stent systems (stents with delivery system)	34
12.2.4	Record label	34
12.3	Information supplied by the manufacturer	34
12.3.1	General	34
12.3.2	Information and instructions for use for stents and/or stent systems	35
Annex A	(informative) Relationship between testing requirements, device attributes, and potential failure modes and guidance for the creation of a device evaluation strategy	36
Annex B	(informative) Description of clinical effects of failure	53
Annex C	(informative) Description of device effects of failure	56
Annex D	(informative) Test methods	58
Bibliography	113

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 285, *Non-active surgical implants*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This third edition cancels and replaces the second edition (ISO 25539-2:2012), which has been technically revised.

The main changes compared to the previous edition are updates to the testing and clinical use of vascular stents as well as improved consistency in nomenclature and reporting requirements.

A list of all parts in the ISO 25539 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document was prepared to provide minimum requirements for vascular stents. The rationale for the requirements for bench tests and analyses to assess device performance, guidance on the identification of appropriate testing to evaluate a specific device design, and guidance for developing test methods are provided in informative annexes. Further clarification of terminology is provided in additional informative annexes.

This document has been updated to reflect current knowledge regarding the testing and clinical use of vascular stents, reflected in modifications to the requirements in the main body and in the guidance for developing test methods in [Annex D](#). In addition, revisions have been made to improve consistency in nomenclature and reporting and to enhance the utility of this document.

Requirements particular to the evaluation of specific characteristics of stents (e.g. coatings, drug-elution, absorption) are incorporated by reference to appropriate standards. However, not all tests listed in the referenced standards are applicable to vascular stents. Only tests that address the design attributes specified in [Clause 6](#) are required for compliance to this document.

This revised document introduces methodology to identify appropriate testing and analyses for a specific vascular stent, designated as the device evaluation strategy. The requirement regarding the device evaluation strategy is in the main body. [Annex A](#) provides guidance for developing a focused device evaluation strategy table that is specific to the unique characteristics of a device, device design modifications, or changes in intended use. [Annex A](#) also provides guidance for the development of a comprehensive device evaluation strategy table that may be used when it is not sufficient to focus only on the unique characteristics or changes.

NOTE ISO 25539-1:2017 includes tables that can be used to justify the testing needed for device design modifications and changes in intended use in [Annex A](#). In this document, this concept is called a focused device evaluation strategy table and can be applied to a new device as well as device design modifications or changes in the intended use.

The other significant modifications in the requirements include the addition of non-radial durability testing, with guidance on the selection of appropriate testing, and specific requirements for testing to evaluate patency-related characteristics. Guidance for the development of appropriate tests to meet these requirements is included in [Annex D](#).

The guidance on the development of methods to address the requirement for evaluating fatigue and durability through computational analyses has been modified significantly to include recommendations regarding verification of the solution and validation of the computational model, as well as reporting. The guidance on the model development for simulated use has also been significantly revised to improve the clinical relevance of this testing.

The specific requirements to evaluate pushability, flexibility, torquability, trackability, and deployment accuracy of a stent system have been removed and incorporated within the simulated use evaluation requirement to better reflect how these attributes are evaluated. Similarly, the requirement to evaluate tubing tensile strength has been removed and incorporated within the evaluation of tensile bond strength.

In addition to modifications to specific design evaluation requirements, guidance has been provided regarding the assessment of the acceptability of test results. When the requirement is to quantitatively appraise or analyse a parameter, test results generally may be compared to a quantitative value (i.e. acceptance criteria). For characterization tests it is appropriate to provide an explanation of the relevance of the results. Additionally, some testing may include comparison to test data or existing data from a previously evaluated device.

For design evaluation, requirements regarding sampling, conditioning of test samples, and reporting have been incorporated in the main body. Guidance on these elements of testing and documentation were previously only included in [Annex D](#).

The revisions to the annexes to this document are as follows:

Annex of ISO 25539-2:2012	Revision
Annex A — Attributes of endovascular devices — Vascular stents — Technical and clinical considerations	Annex A now includes the relationship between testing requirements, device attributes, and potential failure modes and guidance for the creation of a device evaluation strategy.
Annex B — Bench and analytical tests	The list of tests is included in Table D.1. Annex B now includes a description of potential clinical effects of failure. Effects of failure for stents used with endovascular prostheses are included.
Annex C — Definitions of reportable clinical events	The term “reportable” clinical events is no longer used in this document. Annex C now includes a description of potential device effects of failure. Effects of failure for stents used with endovascular prostheses are included.
Annex D — Test methods	This edition incorporates the sample equations as a supplement to the radial fatigue durability test from ISO 25539-2:2012, Annex E in Annex D .
Annex E — Supplement to the radial fatigue and durability test analytical approach	There is no longer an Annex E as the sample equations as a supplement to the fatigue durability test have been incorporated in Annex D .

It is recognized by this ISO committee that many stent systems have been shown to be safe and effective in clinical use. This update is not intended to require additional evaluation of these devices to remain in compliance with this document as the testing would not provide useful information regarding the expected clinical performance of the device. Manufacturers may rely on historical data gathered under the guidance of the previous edition of ISO 25539-2. Similarly, for device modifications or changes in intended clinical use, this update is not intended to require additional evaluation of any aspects of the device that are not expected to change clinical performance.

NOTE The relationship between testing requirements, device attributes, and potential failure modes is provided in [Clause A.1](#). [Clause A.1](#) also provides general information regarding device evaluation strategies. [Tables A.2](#) and [A.3](#) provide the rationale for the requirements specified in this document for bench tests and analyses to assess device performance. An explanation of the table headings for [A.2](#) and [A.3](#) are described in [Table A.1](#).

Guidance for the creation of a device-specific evaluation strategy is provided in [Clause A.2](#). Two approaches to create a device-specific evaluation strategy are provided: 1) focused device evaluation strategy in [A.2.1](#); and 2) comprehensive device evaluation strategy in [A.2.2](#).

[Annex B](#) provides a description of the potential clinical effects of failure identified in [Annex A](#).

[Annex C](#) provides a description of the potential device effects of failure identified in [Annex A](#).

Additional descriptions of clinical and device effects of failure are included in [Annexes B](#) and [C](#), respectively.

[Annex D](#) provides information to consider in developing appropriate bench test and analytical methods.

Cardiovascular implants — Endovascular devices —

Part 2: Vascular stents

1 Scope

This document specifies requirements for the evaluation of stent systems (vascular stents and delivery systems) and requirements with respect to nomenclature, design attributes and information supplied by the manufacturer, based upon current medical knowledge. Guidance for the development of *in vitro* test methods is included in [Annex D](#). This document is supplemental to ISO 14630, which specifies general requirements for the performance of non-active surgical implants.

NOTE 1 Due to the variations in the design of implants covered by this document, and in some cases due to the emergence of novel types of such implants, acceptable standardized *in vitro* tests and clinical results are not always available. As further scientific and clinical data become available, appropriate revision of this document will be necessary.

This document is applicable to vascular stents and vascular scaffolds (e.g. absorbable vascular scaffolds) used to treat vascular stenoses or other vascular abnormalities or pathologies. Some of the requirements are specific to endovascular treatment of arterial stenoses. Although uses of stent systems other than treatment of arterial stenoses (e.g. venous stenting) are within the scope of this document, comprehensive requirements and testing are not described for these uses. Similarly, specific stent configurations (e.g. bifurcation stents) are within the scope, but comprehensive requirements and testing are not described for these devices.

Stents used in combination with an endovascular prosthesis to complete the treatment of a lesion, including bridging stents (e.g. stents placed in the renal arteries after deployment of a fenestrated endovascular prosthesis), are within the scope of this document, but test methods are not described for the combination. ISO 25539-1 also provides information relevant to the preclinical *in vivo* and clinical evaluations of such stents.

Vascular stents that have surface modifications, such as drug and/or other coatings, are within the scope of this document. Stents covered with materials that significantly modify the permeability of the uncovered stent (e.g. by covering the stent-free-surface area) are within the scope of ISO 25539-1. The stent design or intended use might dictate the need to address functional requirements identified in both ISO 25539-1 and this document (e.g. stents used in combination with endovascular prostheses, stents used to treat aortic aneurysms).

Balloons integral to the stent system are within the scope of this document. This document provides requirements beyond the requirements of ISO 10555-4, which are specific to the use of balloons with vascular stents.

This document is not applicable to procedures and devices used prior to the introduction of the vascular stent, such as balloon angioplasty devices.

Tacking devices intended to spot treat post-angioplasty dissections, coil supporting devices, and flow diverters are within the scope of this document, but comprehensive requirements and testing are not described for these devices.

Although drug-eluting stents are within the scope of this document, this document is not comprehensive with respect to the drug-eluting properties of these devices.

NOTE 2 Vascular device-drug combination products are within the scope of ISO 12417-1.

Although absorbable stents and stents with absorbable coatings are within the scope of this document, this document is not comprehensive with respect to the absorbable properties of these devices.

NOTE 3 Absorbable implants are within the scope of ISO/TS 17137.

Although coated stents and coated stent systems are within the scope of this document, this document is not comprehensive with respect to coatings.

NOTE 4 Some coating properties are within the scope of ISO 17327-1.

This document does not address the requirements for, and the evaluation of, viable tissues and non-viable biologic materials used in the construction of vascular stents.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993 (all parts), *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137 (all parts), *Sterilization of health care products — Radiation*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*

ISO 14160, *Sterilization of health care products — Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives — Requirements for characterization, development, validation and routine control of a sterilization process for medical devices*

ISO 14630, *Non-active surgical implants — General requirements*

ISO 14937, *Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices*

ISO 14971, *Medical devices — Application of risk management to medical devices*

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

ASTM F2503, *Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 14630 apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>